{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T16:15:46Z","timestamp":1789748146799,"version":"4.0.1"},"reference-count":203,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T00:00:00Z","timestamp":1654560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T00:00:00Z","timestamp":1654560000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000065","name":"U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01NS071122-07A1"],"award-info":[{"award-number":["R01NS071122-07A1"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["T32-NS082128"],"award-info":[{"award-number":["T32-NS082128"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA026947-10"],"award-info":[{"award-number":["R01DA026947-10"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000052","name":"U.S. Department of Health & Human Services | NIH | NIH Office of the Director","doi-asserted-by":"publisher","award":["1S10OD020026-01"],"award-info":[{"award-number":["1S10OD020026-01"]}],"id":[{"id":"10.13039\/100000052","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["TL1TR001428"],"award-info":[{"award-number":["TL1TR001428"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR001427"],"award-info":[{"award-number":["UL1TR001427"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["TL1TR001428"],"award-info":[{"award-number":["TL1TR001428"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR001427"],"award-info":[{"award-number":["UL1TR001427"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences"},{"name":"U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke"},{"name":"The Karen Toffler Charitable Trust, Bryan Robinson Foundation, University of Florida McKnight Brain Institute"},{"name":"U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences"},{"name":"U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Parkinsons Dis."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Parkinson\u2019s disease (PD) is marked by a loss of dopamine neurons, decreased dopamine transporter (DAT) and tyrosine hydroxylase (TH) expression. However, this validation approach cannot be used for diagnostic, drug effectiveness or investigational purposes in human patients because midbrain tissue is accessible postmortem. PD pathology affects both the central nervous and peripheral immune systems. Therefore, we immunophenotyped blood samples of PD patients for the presence of myeloid derived suppressor cells (MDSCs) and discovered that DAT<jats:sup>+<\/jats:sup>\/TH<jats:sup>+<\/jats:sup>monocytic MDSCs, but not granulocytic MDSCs are increased, suggesting a targeted immune response to PD. Because in peripheral immune cells DAT activity underlies an immune suppressive mechanism, we investigated whether expression levels of DAT and TH in the peripheral immune cells marks PD. We found drug na\u00efve PD patients exhibit differential DAT<jats:sup>+<\/jats:sup>\/TH<jats:sup>+<\/jats:sup>expression in peripheral blood mononuclear cells (PBMCs) compared to aged\/sex matched healthy subjects. While total PBMCs are not different between the groups, the percentage of DAT<jats:sup>+<\/jats:sup>\/TH<jats:sup>+<\/jats:sup>PBMCs was significantly higher in drug na\u00efve PD patients compared to healthy controls irrespective of age, gender, disease duration, disease severity or treatment type. Importantly, treatment for PD negatively modulates DAT<jats:sup>+<\/jats:sup>\/TH<jats:sup>+<\/jats:sup>expressing PBMCs. Neither total nor the percentage of DAT<jats:sup>+<\/jats:sup>\/TH<jats:sup>+<\/jats:sup>PBMCs were altered in the Alzheimer\u2019s disease cohort. The mechanistic underpinning of this discovery in human PD was revealed when these findings were recapitulated in animal models of PD. The reverse translational experimental strategy revealed that alterations in dopaminergic markers in peripheral immune cells are due to the disease associated changes in the CNS. Our study demonstrates that the dopaminergic machinery on peripheral immune cells displays an association with human PD, with exciting implications in facilitating diagnosis and investigation of human PD pathophysiology.<\/jats:p>","DOI":"10.1038\/s41531-022-00333-8","type":"journal-article","created":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T10:05:32Z","timestamp":1654596332000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["DAT and TH expression marks human Parkinson\u2019s disease in peripheral immune cells"],"prefix":"10.1038","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6674-2301","authenticated-orcid":false,"given":"Adithya","family":"Gopinath","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip","family":"Mackie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1491-4885","authenticated-orcid":false,"given":"Basil","family":"Hashimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4933-5170","authenticated-orcid":false,"given":"Anna Marie","family":"Buchanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7242-0926","authenticated-orcid":false,"given":"Aidan R.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Bouchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerry","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Badov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3707-819X","authenticated-orcid":false,"given":"Leila","family":"Saadatpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aryn","family":"Gittis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adolfo","family":"Ramirez-Zamora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Okun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang J.","family":"Streit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parastoo","family":"Hashemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1533-8771","authenticated-orcid":false,"given":"Habibeh","family":"Khoshbouei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,7]]},"reference":[{"key":"333_CR1","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1016\/S1474-4422(09)70238-8","volume":"8","author":"DW Dickson","year":"2009","unstructured":"Dickson, D. W. et al. Neuropathological assessment of Parkinson\u2019s disease: refining the diagnostic criteria. Lancet Neurol. 8, 1150\u20131157 (2009).","journal-title":"Lancet Neurol."},{"key":"333_CR2","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s00401-011-0852-9","volume":"122","author":"GM Halliday","year":"2011","unstructured":"Halliday, G. M., Holton, J. L., Revesz, T. & Dickson, D. W. Neuropathology underlying clinical variability in patients with synucleinopathies. Acta Neuropathol. 122, 187\u2013204 (2011).","journal-title":"Acta Neuropathol."},{"key":"333_CR3","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1093\/brain\/114.5.2283","volume":"114","author":"JM Fearnley","year":"1991","unstructured":"Fearnley, J. M. & Lees, A. J. Ageing and Parkinson\u2019s disease: substantia nigra regional selectivity. Brain 114, 2283\u20132301 (1991).","journal-title":"Brain"},{"key":"333_CR4","first-page":"1437","volume":"122","author":"P Damier","year":"1999","unstructured":"Damier, P., Hirsch, E. C., Agid, Y. & Graybiel, A. M. The substantia nigra of the human brain. II. Patterns loss dopamine-containing neurons Parkinson\u2019s Dis. Brain 122, 1437\u20131448 (1999).","journal-title":"Patterns loss dopamine-containing neurons Parkinson\u2019s Dis. Brain"},{"key":"333_CR5","doi-asserted-by":"publisher","first-page":"455","DOI":"10.3389\/fneur.2018.00455","volume":"9","author":"N Gigu\u00e8re","year":"2018","unstructured":"Gigu\u00e8re, N., Burke Nanni, S. & Trudeau, L.-E. On cell loss and selective vulnerability of neuronal populations in Parkinson\u2019s disease. Front. in Neurol 9, 455, https:\/\/doi.org\/10.3389\/fneur.2018.00455 (2018).","journal-title":"Front. in Neurol"},{"key":"333_CR6","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/S0896-6273(03)00568-3","volume":"39","author":"W Dauer","year":"2003","unstructured":"Dauer, W. & Przedborski, S. Parkinson\u2019s disease: mechanisms and models. Neuron 39, 889\u2013909 (2003).","journal-title":"Neuron"},{"key":"333_CR7","doi-asserted-by":"publisher","first-page":"S671","DOI":"10.1002\/mds.22600","volume":"24","author":"W Poewe","year":"2009","unstructured":"Poewe, W. Clinical measures of progression in Parkinson\u2019s disease. Mov. Disord. 24, S671\u2013S676 (2009).","journal-title":"Mov. Disord."},{"key":"333_CR8","doi-asserted-by":"publisher","first-page":"S119","DOI":"10.1016\/j.parkreldis.2015.09.004","volume":"22","author":"RF Pfeiffer","year":"2016","unstructured":"Pfeiffer, R. F. Non-motor symptoms in Parkinson\u2019s disease. Parkinsonism Relat. Disord. 22, S119\u2013S122 (2016).","journal-title":"Parkinsonism Relat. Disord."},{"key":"333_CR9","doi-asserted-by":"publisher","first-page":"143","DOI":"10.5152\/npa.2016.12758","volume":"54","author":"E G\u00f6k\u00e7al","year":"2017","unstructured":"G\u00f6k\u00e7al, E., G\u00fcr, V. E., Selvitop, R., Babacan Yildiz, G. & Asil, T. Motor and non-motor symptoms in Parkinson\u2019s disease: effects on quality of life. Noro Psikiyatr Ars 54, 143\u2013148 (2017).","journal-title":"Noro Psikiyatr Ars"},{"key":"333_CR10","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1001\/jama.2019.22360","volume":"323","author":"MJ Armstrong","year":"2020","unstructured":"Armstrong, M. J. & Okun, M. S. Diagnosis and treatment of Parkinson disease: a review. JAMA 323, 548\u2013560 (2020).","journal-title":"JAMA"},{"key":"333_CR11","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/ene.14108","volume":"27","author":"R Balestrino","year":"2020","unstructured":"Balestrino, R. & Schapira, A. H. V. Parkinson disease. Eur. J. Neurol. 27, 27\u201342 (2020).","journal-title":"Eur. J. Neurol."},{"key":"333_CR12","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/bs.pbr.2020.02.004","volume":"252","author":"KZ Kuter","year":"2020","unstructured":"Kuter, K. Z., Cenci, M. A. & Carta, A. R. The role of glia in Parkinson\u2019s disease: emerging concepts and therapeutic applications. Prog. Brain Res 252, 131\u2013168 (2020).","journal-title":"Prog. Brain Res"},{"key":"333_CR13","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1097\/00019052-200108000-00009","volume":"14","author":"M Vila","year":"2001","unstructured":"Vila, M. et al. The role of glial cells in Parkinson\u2019s disease. Curr. Opin. Neurol. 14, 483\u2013489 (2001).","journal-title":"Curr. Opin. Neurol."},{"key":"333_CR14","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1124\/jpet.120.265058","volume":"375","author":"A Gopinath","year":"2020","unstructured":"Gopinath, A., Collins, A., Khoshbouei, H. & Streit, W. J. Microglia and other myeloid cells in central nervous system health and disease. J. Pharm. Exp. Ther. 375, 154\u2013160 (2020).","journal-title":"J. Pharm. Exp. Ther."},{"key":"333_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-71329-8","volume":"10","author":"T-M Sonninen","year":"2020","unstructured":"Sonninen, T.-M. et al. Metabolic alterations in Parkinson\u2019s disease astrocytes. Sci. Rep. 10, 14474 (2020).","journal-title":"Sci. Rep."},{"key":"333_CR16","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1002\/ana.25557","volume":"86","author":"V Grozdanov","year":"2019","unstructured":"Grozdanov, V. et al. Increased immune activation by pathologic \u03b1-Synuclein in Parkinson\u2019s disease. Ann. Neurol. 86, 593\u2013606 (2019).","journal-title":"Ann. Neurol."},{"key":"333_CR17","doi-asserted-by":"publisher","first-page":"860","DOI":"10.3389\/fneur.2018.00860","volume":"9","author":"P Troncoso-Escudero","year":"2018","unstructured":"Troncoso-Escudero, P., Parra, A., Nassif, M. & Vidal, R. L. Outside in: unraveling the role of neuroinflammation in the progression of Parkinson\u2019s disease. Front Neurol. 9, 860 (2018).","journal-title":"Front Neurol."},{"key":"333_CR18","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.autrev.2016.07.022","volume":"15","author":"A De Virgilio","year":"2016","unstructured":"De Virgilio, A. et al. Parkinson\u2019s disease: autoimmunity and neuroinflammation. Autoimmun. Rev. 15, 1005\u20131011 (2016).","journal-title":"Autoimmun. Rev."},{"key":"333_CR19","doi-asserted-by":"publisher","first-page":"e71634","DOI":"10.1371\/journal.pone.0071634","volume":"8","author":"SJ Gardai","year":"2013","unstructured":"Gardai, S. J. et al. Elevated alpha-synuclein impairs innate immune cell function and provides a potential peripheral biomarker for Parkinson\u2019s disease. PLoS One 8, e71634 (2013).","journal-title":"PLoS One"},{"key":"333_CR20","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s41531-021-00201-x","volume":"7","author":"A Gopinath","year":"2021","unstructured":"Gopinath, A. et al. TNF\u03b1 increases tyrosine hydroxylase expression in human monocytes. NPJ Parkinsons Dis. 7, 62 (2021).","journal-title":"NPJ Parkinsons Dis."},{"key":"333_CR21","doi-asserted-by":"publisher","first-page":"112686","DOI":"10.1016\/j.jim.2019.112686","volume":"476","author":"A Gopinath","year":"2020","unstructured":"Gopinath, A. et al. A novel approach to study markers of dopamine signaling in peripheral immune cells. J. Immunol. Methods 476, 112686 (2020).","journal-title":"J. Immunol. Methods"},{"key":"333_CR22","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/s41582-020-0344-4","volume":"16","author":"E-K Tan","year":"2020","unstructured":"Tan, E.-K. et al. Parkinson disease and the immune system\u2013\u2013associations, mechanisms and therapeutics. Nat. Rev. Neurol. 16, 303\u2013318 (2020).","journal-title":"Nat. Rev. Neurol."},{"key":"333_CR23","doi-asserted-by":"publisher","first-page":"e13022","DOI":"10.1111\/sji.13022","volume":"93","author":"M \u00d6berg","year":"2021","unstructured":"\u00d6berg, M., Fabrik, I., Fabrikova, D., Zehetner, N. & H\u00e4rtlova, A. The role of innate immunity and inflammation in Parkinson\u00b4s disease. Scand. J. Immunol. 93, e13022 (2021).","journal-title":"Scand. J. Immunol."},{"key":"333_CR24","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1056\/NEJM197809282991302","volume":"299","author":"PM Hoffman","year":"1978","unstructured":"Hoffman, P. M., Robbins, D. S., Nolte, M. T., Gibbs, C. J. Jr. & Gajdusek, D. C. Cellular immunity in Guamanians with amyotrophic lateral sclerosis and Parkinsonism-dementia. N. Engl. J. Med 299, 680\u2013685 (1978).","journal-title":"N. Engl. J. Med"},{"key":"333_CR25","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/S0165-5728(00)00422-7","volume":"113","author":"J Bas","year":"2001","unstructured":"Bas, J. et al. Lymphocyte populations in Parkinson\u2019s disease and in rat models of parkinsonism. J. Neuroimmunol. 113, 146\u2013152 (2001).","journal-title":"J. Neuroimmunol."},{"key":"333_CR26","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.parkreldis.2005.07.005","volume":"11","author":"Y Baba","year":"2005","unstructured":"Baba, Y., Kuroiwa, A., Uitti, R. J., Wszolek, Z. K. & Yamada, T. Alterations of T-lymphocyte populations in Parkinson disease. Parkinsonism Relat. Disord. 11, 493\u2013498 (2005).","journal-title":"Parkinsonism Relat. Disord."},{"key":"333_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nbd.2009.12.017","volume":"38","author":"M Calopa","year":"2010","unstructured":"Calopa, M., Bas, J., Call\u00e9n, A. & Mestre, M. Apoptosis of peripheral blood lymphocytes in Parkinson patients. Neurobiol. Dis. 38, 1\u20137 (2010).","journal-title":"Neurobiol. Dis."},{"key":"333_CR28","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.bbi.2022.01.007","volume":"101","author":"AA Karikari","year":"2022","unstructured":"Karikari, A. A. et al. Neurodegeneration by \u03b1-synuclein-specific T cells in AAV-A53T-\u03b1-synuclein Parkinson\u2019s disease mice. Brain Behav. Immun. 101, 194\u2013210 (2022).","journal-title":"Brain Behav. Immun."},{"key":"333_CR29","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.coi.2019.07.004","volume":"59","author":"CS Lindestam Arlehamn","year":"2019","unstructured":"Lindestam Arlehamn, C. S., Garretti, F., Sulzer, D. & Sette, A. Roles for the adaptive immune system in Parkinson\u2019s and Alzheimer\u2019s diseases. Curr. Opin. Immunol. 59, 115\u2013120 (2019).","journal-title":"Curr. Opin. Immunol."},{"key":"333_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-018-1248-8","volume":"15","author":"N Kustrimovic","year":"2018","unstructured":"Kustrimovic, N. et al. Parkinson\u2019s disease patients have a complex phenotypic and functional Th1 bias: cross-sectional studies of CD4+ Th1\/Th2\/T17 and Treg in drug-na\u00efve and drug-treated patients. J. Neuroinflammation 15, 205 (2018).","journal-title":"J. Neuroinflammation"},{"key":"333_CR31","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1007\/s11481-012-9402-z","volume":"7","author":"JA Saunders","year":"2012","unstructured":"Saunders, J. A. et al. CD4+ regulatory and effector\/memory T cell subsets profile motor dysfunction in Parkinson\u2019s disease. J. Neuroimmune Pharm. 7, 927\u2013938, https:\/\/doi.org\/10.1007\/s11481-012-9402-z (2012).","journal-title":"J. Neuroimmune Pharm."},{"key":"333_CR32","first-page":"182","volume":"119","author":"V Brochard","year":"2009","unstructured":"Brochard, V. et al. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J. Clin. Invest 119, 182\u2013192 (2009).","journal-title":"J. Clin. Invest"},{"key":"333_CR33","doi-asserted-by":"publisher","first-page":"3717","DOI":"10.1093\/brain\/awaa269","volume":"143","author":"J Galiano-Landeira","year":"2020","unstructured":"Galiano-Landeira, J., Torra, A., Vila, M. & Bov\u00e9, J. CD8 T cell nigral infiltration precedes synucleinopathy in early stages of Parkinson\u2019s disease. Brain 143, 3717\u20133733 (2020).","journal-title":"Brain"},{"key":"333_CR34","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s12640-017-9712-2","volume":"32","author":"G Ambrosi","year":"2017","unstructured":"Ambrosi, G. et al. Complex changes in the innate and adaptive immunity accompany progressive degeneration of the nigrostriatal pathway induced by intrastriatal injection of 6-Hydroxydopamine in the rat. Neurotox. Res 32, 71\u201381 (2017).","journal-title":"Neurotox. Res"},{"key":"333_CR35","doi-asserted-by":"publisher","first-page":"303","DOI":"10.3389\/fimmu.2019.00303","volume":"10","author":"F Garretti","year":"2019","unstructured":"Garretti, F., Agalliu, D., Lindestam Arlehamn, C. S., Sette, A. & Sulzer, D. Autoimmunity in Parkinson\u2019s Disease: the Role of \u03b1-Synuclein-Specific T Cells. Front Immunol. 10, 303 (2019).","journal-title":"Front Immunol."},{"key":"333_CR36","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/nature22815","volume":"546","author":"D Sulzer","year":"2017","unstructured":"Sulzer, D. et al. T cells from patients with Parkinson\u2019s disease recognize \u03b1-synuclein peptides. Nature 546, 656\u2013661 (2017).","journal-title":"Nature"},{"key":"333_CR37","doi-asserted-by":"publisher","first-page":"3719","DOI":"10.2174\/0929867325666181009161048","volume":"26","author":"N Kustrimovic","year":"2019","unstructured":"Kustrimovic, N., Marino, F. & Cosentino, M. Peripheral Immunity, Immunoaging and Neuroinflammation in Parkinson\u2019s Disease. Curr. Med Chem. 26, 3719\u20133753 (2019).","journal-title":"Curr. Med Chem."},{"key":"333_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/srep33738","volume":"6","author":"N Kustrimovic","year":"2016","unstructured":"Kustrimovic, N. et al. Dopaminergic receptors on CD4+ T naive and memory lymphocytes correlate with motor impairment in patients with Parkinson\u2019s disease. Sci. Rep. 6, 33738 (2016).","journal-title":"Sci. Rep."},{"key":"333_CR39","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1007\/s11481-014-9541-5","volume":"9","author":"N Kustrimovic","year":"2014","unstructured":"Kustrimovic, N., Rasini, E., Legnaro, M., Marino, F. & Cosentino, M. Expression of dopaminergic receptors on human CD4+ T lymphocytes: flow cytometric analysis of naive and memory subsets and relevance for the neuroimmunology of neurodegenerative disease. J. Neuroimmune Pharm. 9, 302\u2013312 (2014).","journal-title":"J. Neuroimmune Pharm."},{"key":"333_CR40","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s40478-017-0494-9","volume":"5","author":"AS Harms","year":"2017","unstructured":"Harms, A. S. et al. \u03b1-Synuclein fibrils recruit peripheral immune cells in the rat brain prior to neurodegeneration. Acta Neuropathol. Commun. 5, 85 (2017).","journal-title":"Acta Neuropathol. Commun."},{"key":"333_CR41","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.expneurol.2017.11.010","volume":"300","author":"AS Harms","year":"2018","unstructured":"Harms, A. S. et al. Peripheral monocyte entry is required for alpha-Synuclein induced inflammation and Neurodegeneration in a model of Parkinson disease. Exp. Neurol. 300, 179\u2013187 (2018).","journal-title":"Exp. Neurol."},{"key":"333_CR42","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/mds.28411","volume":"36","author":"EM Kline","year":"2021","unstructured":"Kline, E. M. et al. Genetic and environmental factors in Parkinson\u2019s disease converge on immune function and inflammation. Mov. Disord. 36, 25\u201336 (2021).","journal-title":"Mov. Disord."},{"key":"333_CR43","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/ejn.14290","volume":"49","author":"MG Tansey","year":"2019","unstructured":"Tansey, M. G. & Romero-Ramos, M. Immune system responses in Parkinson\u2019s disease: early and dynamic. Eur. J. Neurosci. 49, 364\u2013383 (2019).","journal-title":"Eur. J. Neurosci."},{"key":"333_CR44","doi-asserted-by":"publisher","first-page":"257","DOI":"10.2174\/1568010023344599","volume":"1","author":"T Hosoi","year":"2002","unstructured":"Hosoi, T., Okuma, Y. & Nomura, Y. The mechanisms of immune-to-brain communication in inflammation as a drug target. Curr. Drug Targets Inflamm. Allergy 1, 257\u2013262 (2002).","journal-title":"Curr. Drug Targets Inflamm. Allergy"},{"key":"333_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11064-010-0252-x","volume":"36","author":"HO Besedovsky","year":"2011","unstructured":"Besedovsky, H. O. & del Rey, A. Central and peripheral cytokines mediate immune-brain connectivity. Neurochem Res 36, 1\u20136 (2011).","journal-title":"Neurochem Res"},{"key":"333_CR46","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S0889-1591(03)00032-1","volume":"17","author":"SF Maier","year":"2003","unstructured":"Maier, S. F. Bi-directional immune-brain communication: implications for understanding stress, pain, and cognition. Brain Behav. Immun. 17, 69\u201385 (2003).","journal-title":"Brain Behav. Immun."},{"key":"333_CR47","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1007\/s11481-019-09851-4","volume":"15","author":"SM Matt","year":"2020","unstructured":"Matt, S. M. & Gaskill, P. J. Where is dopamine and how do immune cells see it?: dopamine-mediated immune cell function in health and disease. J. Neuroimmune Pharm. 15, 114\u2013164 (2020).","journal-title":"J. Neuroimmune Pharm."},{"key":"333_CR48","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1080\/08830185.2017.1357719","volume":"37","author":"N Negi","year":"2018","unstructured":"Negi, N. & Das, B. K. CNS: not an immunoprivilaged site anymore but a virtual secondary lymphoid organ. Int Rev. Immunol. 37, 57\u201368 (2018).","journal-title":"Int Rev. Immunol."},{"key":"333_CR49","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1159\/000104864","volume":"13","author":"D Lorton","year":"2006","unstructured":"Lorton, D. et al. Bidirectional communication between the brain and the immune system: implications for physiological sleep and disorders with disrupted sleep. Neuroimmunomodulation 13, 357\u2013374 (2006).","journal-title":"Neuroimmunomodulation"},{"key":"333_CR50","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41577-020-0387-1","volume":"21","author":"M Schiller","year":"2021","unstructured":"Schiller, M., Ben-Shaanan, T. L. & Rolls, A. Neuronal regulation of immunity: why, how and where? Nat. Rev. Immunol. 21, 20\u201336 (2021).","journal-title":"Nat. Rev. Immunol."},{"key":"333_CR51","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1038\/nm.4340","volume":"23","author":"JM Garr\u00e9","year":"2017","unstructured":"Garr\u00e9, J. M., Silva, H. M., Lafaille, J. J. & Yang, G. CX3CR1(+) monocytes modulate learning and learning-dependent dendritic spine remodeling via TNF-\u03b1. Nat. Med 23, 714\u2013722 (2017).","journal-title":"Nat. Med"},{"key":"333_CR52","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/s41577-021-00508-z","volume":"21","author":"AF Salvador","year":"2021","unstructured":"Salvador, A. F., de Lima, K. A. & Kipnis, J. Neuromodulation by the immune system: a focus on cytokines. Nat. Rev. Immunol. 21, 526\u2013541 (2021).","journal-title":"Nat. Rev. Immunol."},{"key":"333_CR53","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.3389\/fimmu.2019.02035","volume":"10","author":"TS Kapellos","year":"2019","unstructured":"Kapellos, T. S. et al. Human monocyte subsets and phenotypes in major chronic inflammatory diseases. Front Immunol. 10, 2035 (2019).","journal-title":"Front Immunol."},{"key":"333_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-61022-1","volume":"10","author":"F Merah-Mourah","year":"2020","unstructured":"Merah-Mourah, F., Cohen, S. O., Charron, D., Mooney, N. & Haziot, A. Identification of novel human monocyte subsets and evidence for phenotypic groups defined by interindividual variations of expression of adhesion molecules. Sci. Rep. 10, 4397 (2020).","journal-title":"Sci. Rep."},{"key":"333_CR55","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.bbi.2018.03.020","volume":"70","author":"P Mackie","year":"2018","unstructured":"Mackie, P. et al. The dopamine transporter: an unrecognized nexus for dysfunctional peripheral immunity and signaling in Parkinson\u2019s Disease. Brain Behav. Immun. 70, 21\u201335 (2018).","journal-title":"Brain Behav. Immun."},{"key":"333_CR56","doi-asserted-by":"publisher","first-page":"3864","DOI":"10.1210\/jcem.82.11.4339","volume":"82","author":"G Eisenhofer","year":"1997","unstructured":"Eisenhofer, G. et al. Substantial production of dopamine in the human gastrointestinal tract. J. Clin. Endocrinol. Metab. 82, 3864\u20133871 (1997).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"333_CR57","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.jneuroim.2008.09.018","volume":"206","author":"F Mignini","year":"2009","unstructured":"Mignini, F., Tomassoni, D., Traini, E. & Amenta, F. Dopamine, vesicular transporters and dopamine receptor expression and localization in rat thymus and spleen. J. Neuroimmunol. 206, 5\u201313 (2009).","journal-title":"J. Neuroimmunol."},{"key":"333_CR58","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s11481-017-9726-9","volume":"12","author":"TM Calderon","year":"2017","unstructured":"Calderon, T. M. et al. Dopamine increases CD14(+)CD16(+) monocyte transmigration across the blood brain barrier: implications for substance abuse and HIV neuropathogenesis. J. Neuroimmune Pharm. 12, 353\u2013370 (2017).","journal-title":"J. Neuroimmune Pharm."},{"key":"333_CR59","doi-asserted-by":"publisher","first-page":"e0117450","DOI":"10.1371\/journal.pone.0117450","volume":"10","author":"JS Coley","year":"2015","unstructured":"Coley, J. S., Calderon, T. M., Gaskill, P. J., Eugenin, E. A. & Berman, J. W. Dopamine increases CD14+CD16+ monocyte migration and adhesion in the context of substance abuse and HIV neuropathogenesis. PLoS One 10, e0117450 (2015).","journal-title":"PLoS One"},{"key":"333_CR60","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.2353\/ajpath.2009.081067","volume":"175","author":"PJ Gaskill","year":"2009","unstructured":"Gaskill, P. J. et al. Human immunodeficiency virus (HIV) infection of human macrophages is increased by dopamine: a bridge between HIV-associated neurologic disorders and drug abuse. Am. J. Pathol. 175, 1148\u20131159 (2009).","journal-title":"Am. J. Pathol."},{"key":"333_CR61","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-9-203","volume":"9","author":"PJ Gaskill","year":"2012","unstructured":"Gaskill, P. J., Carvallo, L., Eugenin, E. A. & Berman, J. W. Characterization and function of the human macrophage dopaminergic system: implications for CNS disease and drug abuse. J. Neuroinflammation 9, 203 (2012).","journal-title":"J. Neuroinflammation"},{"key":"333_CR62","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1007\/s11481-017-9749-2","volume":"12","author":"M Pinoli","year":"2017","unstructured":"Pinoli, M., Marino, F. & Cosentino, M. Dopaminergic regulation of innate immunity: a review. J. Neuroimmune Pharm. 12, 602\u2013623 (2017).","journal-title":"J. Neuroimmune Pharm."},{"key":"333_CR63","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.neuropharm.2016.09.028","volume":"113","author":"D Elgueta","year":"2017","unstructured":"Elgueta, D. et al. Pharmacologic antagonism of dopamine receptor D3 attenuates neurodegeneration and motor impairment in a mouse model of Parkinson\u2019s disease. Neuropharmacology 113, 110\u2013123 (2017).","journal-title":"Neuropharmacology"},{"key":"333_CR64","doi-asserted-by":"publisher","unstructured":"Elgueta, D. et al. Dopamine receptor D3 expression is altered in CD4+ T-cells from parkinson\u2019s disease patients and its pharmacologic inhibition attenuates the motor impairment in a mouse model. Front. in Immunol. 10, https:\/\/doi.org\/10.3389\/fimmu.2019.00981 (2019).","DOI":"10.3389\/fimmu.2019.00981"},{"key":"333_CR65","doi-asserted-by":"publisher","first-page":"5048","DOI":"10.4049\/jimmunol.1203121","volume":"190","author":"H Gonz\u00e1lez","year":"2013","unstructured":"Gonz\u00e1lez, H. et al. Dopamine receptor D3 expressed on CD4+ T cells favors neurodegeneration of dopaminergic neurons during Parkinson\u2019s disease. J. Immunol. 190, 5048\u20135056 (2013).","journal-title":"J. Immunol."},{"key":"333_CR66","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-019-1652-8","volume":"16","author":"A Montoya","year":"2019","unstructured":"Montoya, A. et al. Dopamine receptor D3 signalling in astrocytes promotes neuroinflammation. J. Neuroinflammation 16, 258 (2019).","journal-title":"J. Neuroinflammation"},{"key":"333_CR67","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1136\/annrheumdis-2013-203925","volume":"74","author":"Z Jenei-Lanzl","year":"2015","unstructured":"Jenei-Lanzl, Z. et al. Anti-inflammatory effects of cell-based therapy with tyrosine hydroxylase-positive catecholaminergic cells in experimental arthritis. Ann. Rheum. Dis. 74, 444\u2013451 (2015).","journal-title":"Ann. Rheum. Dis."},{"key":"333_CR68","first-page":"427","volume":"29","author":"LE Miller","year":"2002","unstructured":"Miller, L. E., Grifka, J., Sch\u00f6lmerich, J. & Straub, R. H. Norepinephrine from synovial tyrosine hydroxylase positive cells is a strong indicator of synovial inflammation in rheumatoid arthritis. J. Rheumatol. 29, 427\u2013435 (2002).","journal-title":"J. Rheumatol."},{"key":"333_CR69","doi-asserted-by":"crossref","unstructured":"Mackie, P. M. et al. Functional characterization of the biogenic amine transporters on human macrophages. JCI Insight 7, (2022).","DOI":"10.1172\/jci.insight.151892"},{"key":"333_CR70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00109-020-01988-7","volume":"99","author":"A Salminen","year":"2021","unstructured":"Salminen, A. Increased immunosuppression impairs tissue homeostasis with aging and age-related diseases. J. Mol. Med (Berl.) 99, 1\u201320 (2021).","journal-title":"J. Mol. Med (Berl.)"},{"key":"333_CR71","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1160\/TH08-07-0421","volume":"101","author":"M Adib-Conquy","year":"2009","unstructured":"Adib-Conquy, M. & Cavaillon, J. M. Compensatory anti-inflammatory response syndrome. Thromb. Haemost. 101, 36\u201347 (2009).","journal-title":"Thromb. Haemost."},{"key":"333_CR72","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1097\/TA.0b013e318256e000","volume":"72","author":"LF Gentile","year":"2012","unstructured":"Gentile, L. F. et al. Persistent inflammation and immunosuppression: a common syndrome and new horizon for surgical intensive care. J. Trauma Acute Care Surg. 72, 1491\u20131501 (2012).","journal-title":"J. Trauma Acute Care Surg."},{"key":"333_CR73","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1097\/MOP.0000000000000352","volume":"28","author":"JA Muszynski","year":"2016","unstructured":"Muszynski, J. A., Thakkar, R. & Hall, M. W. Inflammation and innate immune function in critical illness. Curr. Opin. Pediatr. 28, 267\u2013273 (2016).","journal-title":"Curr. Opin. Pediatr."},{"key":"333_CR74","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/0304-3940(94)90746-3","volume":"165","author":"M Mogi","year":"1994","unstructured":"Mogi, M. et al. Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci. Lett. 165, 208\u2013210 (1994).","journal-title":"Neurosci. Lett."},{"key":"333_CR75","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.clineuro.2018.01.022","volume":"166","author":"E Kouchaki","year":"2018","unstructured":"Kouchaki, E. et al. Increased serum levels of TNF-alpha and decreased serum levels of IL-27 in patients with Parkinson disease and their correlation with disease severity. Clin. Neurol. Neurosurg. 166, 76\u201379 (2018).","journal-title":"Clin. Neurol. Neurosurg."},{"key":"333_CR76","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-019-1286-6","volume":"19","author":"D Rathnayake","year":"2019","unstructured":"Rathnayake, D., Chang, T. & Udagama, P. Selected serum cytokines and nitric oxide as potential multi-marker biosignature panels for Parkinson disease of varying durations: a case-control study. BMC Neurol. 19, 56 (2019).","journal-title":"BMC Neurol."},{"key":"333_CR77","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1001\/jamaneurol.2016.2742","volume":"73","author":"XY Qin","year":"2016","unstructured":"Qin, X. Y., Zhang, S. P., Cao, C., Loh, Y. P. & Cheng, Y. Aberrations in peripheral inflammatory cytokine levels in parkinson disease: a systematic review and meta-analysis. JAMA Neurol. 73, 1316\u20131324 (2016).","journal-title":"JAMA Neurol."},{"key":"333_CR78","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-5-45","volume":"5","author":"MK McCoy","year":"2008","unstructured":"McCoy, M. K. & Tansey, M. G. TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease. J. Neuroinflammation 5, 45 (2008).","journal-title":"J. Neuroinflammation"},{"key":"333_CR79","doi-asserted-by":"publisher","first-page":"9365","DOI":"10.1523\/JNEUROSCI.1504-06.2006","volume":"26","author":"MK McCoy","year":"2006","unstructured":"McCoy, M. K. et al. Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson\u2019s disease. J. Neurosci. 26, 9365\u20139375 (2006).","journal-title":"J. Neurosci."},{"key":"333_CR80","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s11481-009-9176-0","volume":"4","author":"JK Lee","year":"2009","unstructured":"Lee, J. K., Tran, T. & Tansey, M. G. Neuroinflammation in Parkinson\u2019s disease. J. Neuroimmune Pharm. 4, 419\u2013429 (2009).","journal-title":"J. Neuroimmune Pharm."},{"key":"333_CR81","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1016\/j.neurobiolaging.2007.04.006","volume":"29","author":"X Su","year":"2008","unstructured":"Su, X. et al. Synuclein activates microglia in a model of Parkinson\u2019s disease. Neurobiol. Aging 29, 1690\u20131701 (2008).","journal-title":"Neurobiol. Aging"},{"key":"333_CR82","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.pneurobio.2005.06.004","volume":"76","author":"ML Block","year":"2005","unstructured":"Block, M. L. & Hong, J. S. Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. Prog. Neurobiol. 76, 77\u201398 (2005).","journal-title":"Prog. Neurobiol."},{"key":"333_CR83","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/emm.2006.40","volume":"38","author":"YS Kim","year":"2006","unstructured":"Kim, Y. S. & Joh, T. H. Microglia, major player in the brain inflammation: their roles in the pathogenesis of Parkinson\u2019s disease. Exp. Mol. Med 38, 333\u2013347 (2006).","journal-title":"Exp. Mol. Med"},{"key":"333_CR84","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.jaci.2014.11.001","volume":"135","author":"F Annunziato","year":"2015","unstructured":"Annunziato, F., Romagnani, C. & Romagnani, S. The 3 major types of innate and adaptive cell-mediated effector immunity. J. Allergy Clin. Immunol. 135, 626\u2013635 (2015).","journal-title":"J. Allergy Clin. Immunol."},{"key":"333_CR85","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1046\/j.1365-2249.1996.d01-740.x","volume":"105","author":"S Goerdt","year":"1996","unstructured":"Goerdt, S., Kodelja, V., Schmuth, M., Orfanos, C. E. & Sorg, C. The mononuclear phagocyte-dendritic cell dichotomy: myths, facts, and a revised concept. Clin. Exp. Immunol. 105, 1\u20139 (1996).","journal-title":"Clin. Exp. Immunol."},{"key":"333_CR86","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12150","volume":"7","author":"V Bronte","year":"2016","unstructured":"Bronte, V. et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat. Commun. 7, 12150 (2016).","journal-title":"Nat. Commun."},{"key":"333_CR87","doi-asserted-by":"publisher","unstructured":"Marimuthu, R. et al. Characterization of human monocyte subsets by whole blood flow cytometry analysis. J Vis Exp, https:\/\/doi.org\/10.3791\/57941 (2018).","DOI":"10.3791\/57941"},{"key":"333_CR88","doi-asserted-by":"publisher","first-page":"423","DOI":"10.3389\/fimmu.2015.00423","volume":"6","author":"L Ziegler-Heitbrock","year":"2015","unstructured":"Ziegler-Heitbrock, L. Blood monocytes and their subsets: established features and open questions. Front Immunol. 6, 423, https:\/\/doi.org\/10.3389\/fimmu.2015.00423 (2015).","journal-title":"Front Immunol."},{"key":"333_CR89","doi-asserted-by":"publisher","first-page":"6166","DOI":"10.4049\/jimmunol.164.12.6166","volume":"164","author":"CD Mills","year":"2000","unstructured":"Mills, C. D., Kincaid, K., Alt, J. M., Heilman, M. J. & Hill, A. M. M-1\/M-2 macrophages and the Th1\/Th2 paradigm. J. Immunol. 164, 6166\u20136173 (2000).","journal-title":"J. Immunol."},{"key":"333_CR90","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1161\/CIRCRESAHA.116.309194","volume":"119","author":"M Nahrendorf","year":"2016","unstructured":"Nahrendorf, M. & Swirski, F. K. Abandoning M1\/M2 for a Network Model of Macrophage Function. Circ. Res 119, 414\u2013417 (2016).","journal-title":"Circ. Res"},{"key":"333_CR91","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1126\/science.1178331","volume":"327","author":"F Geissmann","year":"2010","unstructured":"Geissmann, F. et al. Development of monocytes, macrophages, and dendritic cells. Science 327, 656\u2013661 (2010).","journal-title":"Science"},{"key":"333_CR92","doi-asserted-by":"publisher","unstructured":"Ginhoux, F. et al. Editorial: monocyte heterogeneity and function. Front. in Immunol. 11, https:\/\/doi.org\/10.3389\/fimmu.2020.626725 (2021).","DOI":"10.3389\/fimmu.2020.626725"},{"key":"333_CR93","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/ni.3324","volume":"17","author":"F Ginhoux","year":"2016","unstructured":"Ginhoux, F., Schultze, J. L., Murray, P. J., Ochando, J. & Biswas, S. K. New insights into the multidimensional concept of macrophage ontogeny, activation and function. Nat. Immunol. 17, 34\u201340 (2016).","journal-title":"Nat. Immunol."},{"key":"333_CR94","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1038\/nri3712","volume":"14","author":"M Guilliams","year":"2014","unstructured":"Guilliams, M. et al. Dendritic cells, monocytes and macrophages: a unified nomenclature based on ontogeny. Nat. Rev. Immunol. 14, 571\u2013578 (2014).","journal-title":"Nat. Rev. Immunol."},{"key":"333_CR95","doi-asserted-by":"publisher","unstructured":"Wolf, A. A., Y\u00e1\u00f1ez, A., Barman, P. K. & Goodridge, H. S. The ontogeny of monocyte subsets. Front. in Immunol. 10, https:\/\/doi.org\/10.3389\/fimmu.2019.01642 (2019).","DOI":"10.3389\/fimmu.2019.01642"},{"key":"333_CR96","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.coi.2010.01.021","volume":"22","author":"E Peranzoni","year":"2010","unstructured":"Peranzoni, E. et al. Myeloid-derived suppressor cell heterogeneity and subset definition. Curr. Opin. Immunol. 22, 238\u2013244 (2010).","journal-title":"Curr. Opin. Immunol."},{"key":"333_CR97","doi-asserted-by":"publisher","first-page":"3536","DOI":"10.4049\/jimmunol.168.7.3536","volume":"168","author":"KU Belge","year":"2002","unstructured":"Belge, K. U. et al. The proinflammatory CD14+CD16+DR++ monocytes are a major source of TNF. J. Immunol. 168, 3536\u20133542 (2002).","journal-title":"J. Immunol."},{"key":"333_CR98","doi-asserted-by":"publisher","first-page":"e50","DOI":"10.1182\/blood-2011-01-326827","volume":"118","author":"AM Zawada","year":"2011","unstructured":"Zawada, A. M. et al. SuperSAGE evidence for CD14++CD16+ monocytes as a third monocyte subset. Blood 118, e50\u2013e61 (2011).","journal-title":"Blood"},{"key":"333_CR99","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1002\/cyto.a.22104","volume":"81","author":"RD Abeles","year":"2012","unstructured":"Abeles, R. D. et al. CD14, CD16 and HLA-DR reliably identifies human monocytes and their subsets in the context of pathologically reduced HLA-DR expression by CD14(hi) \/CD16(neg) monocytes: Expansion of CD14(hi) \/CD16(pos) and contraction of CD14(lo) \/CD16(pos) monocytes in acute liver failure. Cytom. A 81, 823\u2013834 (2012).","journal-title":"Cytom. A"},{"key":"333_CR100","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/nyas.12469","volume":"1319","author":"S Solito","year":"2014","unstructured":"Solito, S. et al. Myeloid-derived suppressor cell heterogeneity in human cancers. Ann. N Y Acad. Sci. 1319, 47\u201365 (2014).","journal-title":"Ann. N Y Acad. Sci."},{"key":"333_CR101","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/nrc3581","volume":"13","author":"JE Talmadge","year":"2013","unstructured":"Talmadge, J. E. & Gabrilovich, D. I. History of myeloid-derived suppressor cells. Nat. Rev. Cancer 13, 739\u2013752 (2013).","journal-title":"Nat. Rev. Cancer"},{"key":"333_CR102","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1084\/jem.20132423","volume":"212","author":"L Gao","year":"2015","unstructured":"Gao, L. et al. Infiltration of circulating myeloid cells through CD95L contributes to neurodegeneration in mice. J. Exp. Med 212, 469\u2013480 (2015).","journal-title":"J. Exp. Med"},{"key":"333_CR103","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-017-0830-9","volume":"14","author":"VR Parillaud","year":"2017","unstructured":"Parillaud, V. R. et al. Analysis of monocyte infiltration in MPTP mice reveals that microglial CX3CR1 protects against neurotoxic over-induction of monocyte-attracting CCL2 by astrocytes. J. Neuroinflammation 14, 60 (2017).","journal-title":"J. Neuroinflammation"},{"key":"333_CR104","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1126\/science.1249547","volume":"344","author":"T Raj","year":"2014","unstructured":"Raj, T. et al. Polarization of the effects of autoimmune and neurodegenerative risk alleles in leukocytes. Science 344, 519\u2013523 (2014).","journal-title":"Science"},{"key":"333_CR105","doi-asserted-by":"publisher","first-page":"284","DOI":"10.4049\/jimmunol.176.1.284","volume":"176","author":"SK Bunt","year":"2006","unstructured":"Bunt, S. K., Sinha, P., Clements, V. K., Leips, J. & Ostrand-Rosenberg, S. Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. J. Immunol. 176, 284\u2013290 (2006).","journal-title":"J. Immunol."},{"key":"333_CR106","doi-asserted-by":"publisher","first-page":"10019","DOI":"10.1158\/0008-5472.CAN-07-2354","volume":"67","author":"SK Bunt","year":"2007","unstructured":"Bunt, S. K. et al. Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res 67, 10019\u201310026 (2007).","journal-title":"Cancer Res"},{"key":"333_CR107","doi-asserted-by":"publisher","first-page":"678","DOI":"10.4049\/jimmunol.166.1.678","volume":"166","author":"B Almand","year":"2001","unstructured":"Almand, B. et al. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J. Immunol. 166, 678\u2013689 (2001).","journal-title":"J. Immunol."},{"key":"333_CR108","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/s00262-003-0443-2","volume":"53","author":"P Serafini","year":"2004","unstructured":"Serafini, P. et al. Derangement of immune responses by myeloid suppressor cells. Cancer Immunol. Immunother. 53, 64\u201372 (2004).","journal-title":"Cancer Immunol. Immunother."},{"key":"333_CR109","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41577-020-00490-y","volume":"21","author":"F Veglia","year":"2021","unstructured":"Veglia, F., Sanseviero, E. & Gabrilovich, D. I. Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. Nat. Rev. Immunol. 21, 485\u2013498 (2021).","journal-title":"Nat. Rev. Immunol."},{"key":"333_CR110","doi-asserted-by":"publisher","unstructured":"Cassetta, L. et al. Differential expansion of circulating human MDSC subsets in patients with cancer, infection and inflammation. J Immunother Cancer 8, https:\/\/doi.org\/10.1136\/jitc-2020-001223 (2020).","DOI":"10.1136\/jitc-2020-001223"},{"key":"333_CR111","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-0716-1060-2_1","volume":"2236","author":"K Bruderek","year":"2021","unstructured":"Bruderek, K., Schirrmann, R. & Brandau, S. Immunophenotyping of circulating myeloid-derived suppressor cells (MDSC) in the peripheral blood of cancer patients. Methods Mol. Biol. 2236, 1\u20137 (2021).","journal-title":"Methods Mol. Biol."},{"key":"333_CR112","doi-asserted-by":"publisher","unstructured":"Bergenfelz, C. & Leandersson, K. The Generation and Identity of Human Myeloid-Derived Suppressor Cells. Front. in Oncol. 10, https:\/\/doi.org\/10.3389\/fonc.2020.00109 (2020).","DOI":"10.3389\/fonc.2020.00109"},{"key":"333_CR113","doi-asserted-by":"publisher","first-page":"e0121546","DOI":"10.1371\/journal.pone.0121546","volume":"10","author":"MP Gustafson","year":"2015","unstructured":"Gustafson, M. P. et al. A method for identification and analysis of non-overlapping myeloid immunophenotypes in humans. PLoS One 10, e0121546 (2015).","journal-title":"PLoS One"},{"key":"333_CR114","doi-asserted-by":"publisher","first-page":"122","DOI":"10.3389\/fneur.2019.00122","volume":"10","author":"E Caggiu","year":"2019","unstructured":"Caggiu, E. et al. Inflammation, infectious triggers, and Parkinson\u2019s disease. Front Neurol. 10, 122 (2019).","journal-title":"Front Neurol."},{"key":"333_CR115","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1093\/brain\/awy077","volume":"141","author":"E Kozina","year":"2018","unstructured":"Kozina, E. et al. Mutant LRRK2 mediates peripheral and central immune responses leading to neurodegeneration in vivo. Brain 141, 1753\u20131769 (2018).","journal-title":"Brain"},{"key":"333_CR116","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1111\/j.1600-0404.2007.00894.x","volume":"116","author":"M Rentzos","year":"2007","unstructured":"Rentzos, M. et al. Circulating interleukin-15 and RANTES chemokine in Parkinson\u2019s disease. Acta Neurol. Scand. 116, 374\u2013379 (2007).","journal-title":"Acta Neurol. Scand."},{"key":"333_CR117","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.neulet.2008.06.040","volume":"441","author":"B Brodacki","year":"2008","unstructured":"Brodacki, B. et al. Serum interleukin (IL-2, IL-10, IL-6, IL-4), TNFalpha, and INFgamma concentrations are elevated in patients with atypical and idiopathic parkinsonism. Neurosci. Lett. 441, 158\u2013162 (2008).","journal-title":"Neurosci. Lett."},{"key":"333_CR118","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.parkreldis.2008.05.014","volume":"15","author":"M Dufek","year":"2009","unstructured":"Dufek, M. et al. Serum inflammatory biomarkers in Parkinson\u2019s disease. Parkinsonism Relat. Disord. 15, 318\u2013320 (2009).","journal-title":"Parkinsonism Relat. Disord."},{"key":"333_CR119","doi-asserted-by":"publisher","first-page":"4259","DOI":"10.1007\/s00018-013-1352-y","volume":"70","author":"M Deleidi","year":"2013","unstructured":"Deleidi, M. & Gasser, T. The role of inflammation in sporadic and familial Parkinson\u2019s disease. Cell Mol. Life Sci. 70, 4259\u20134273 (2013).","journal-title":"Cell Mol. Life Sci."},{"key":"333_CR120","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S0165-5728(02)00372-7","volume":"133","author":"M Cosentino","year":"2002","unstructured":"Cosentino, M. et al. Catecholamine production and tyrosine hydroxylase expression in peripheral blood mononuclear cells from multiple sclerosis patients: effect of cell stimulation and possible relevance for activation-induced apoptosis. J. Neuroimmunol. 133, 233\u2013240 (2002).","journal-title":"J. Neuroimmunol."},{"key":"333_CR121","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.cell.2015.12.023","volume":"164","author":"I Gabanyi","year":"2016","unstructured":"Gabanyi, I. et al. Neuro-immune interactions drive tissue programming in intestinal macrophages. Cell 164, 378\u2013391 (2016).","journal-title":"Cell"},{"key":"333_CR122","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.cell.2019.12.002","volume":"180","author":"F Matheis","year":"2020","unstructured":"Matheis, F. et al. Adrenergic signaling in muscularis macrophages limits infection-induced neuronal loss. Cell 180, 64\u201378.e16 (2020).","journal-title":"Cell"},{"key":"333_CR123","doi-asserted-by":"publisher","unstructured":"Mackie, P. M. et al. Functional characterization of the biogenic amine transporter system on human macrophages. bioRxiv, https:\/\/doi.org\/10.1101\/2021.09.08.459459 (2021).","DOI":"10.1101\/2021.09.08.459459"},{"key":"333_CR124","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1097\/SLA.0000000000001783","volume":"265","author":"B Mathias","year":"2017","unstructured":"Mathias, B. et al. Human myeloid-derived suppressor cells are associated with chronic immune suppression after severe sepsis\/septic shock. Ann. Surg. 265, 827\u2013834 (2017).","journal-title":"Ann. Surg."},{"key":"333_CR125","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.parkreldis.2009.09.002","volume":"16","author":"AW Willis","year":"2010","unstructured":"Willis, A. W., Sterling, C. & Racette, B. A. Conjugal Parkinsonism and Parkinson disease: a case series with environmental risk factor analysis. Parkinsonism Relat. Disord. 16, 163\u2013166 (2010).","journal-title":"Parkinsonism Relat. Disord."},{"key":"333_CR126","doi-asserted-by":"publisher","first-page":"218","DOI":"10.3389\/fneur.2019.00218","volume":"10","author":"N Ball","year":"2019","unstructured":"Ball, N., Teo, W. P., Chandra, S. & Chapman, J. Parkinson\u2019s disease and the environment. Front Neurol. 10, 218 (2019).","journal-title":"Front Neurol."},{"key":"333_CR127","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/mds.870110105","volume":"11","author":"G De Michele","year":"1996","unstructured":"De Michele, G. et al. Environmental and genetic risk factors in Parkinson\u2019s disease: a case-control study in southern Italy. Mov. Disord. 11, 17\u201323 (1996).","journal-title":"Mov. Disord."},{"key":"333_CR128","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1023\/B:EJEP.0000006639.05690.92","volume":"18","author":"P Pals","year":"2003","unstructured":"Pals, P. et al. Case-control study of environmental risk factors for Parkinson\u2019s disease in Belgium. Eur. J. Epidemiol. 18, 1133\u20131142 (2003).","journal-title":"Eur. J. Epidemiol."},{"key":"333_CR129","doi-asserted-by":"publisher","first-page":"3340","DOI":"10.1021\/acschemneuro.9b00333","volume":"10","author":"KA Walker","year":"2019","unstructured":"Walker, K. A., Ficek, B. N. & Westbrook, R. Understanding the role of systemic inflammation in Alzheimer\u2019s disease. ACS Chem. Neurosci. 10, 3340\u20133342 (2019).","journal-title":"ACS Chem. Neurosci."},{"key":"333_CR130","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1212\/WNL.0b013e3181b6bb95","volume":"73","author":"C Holmes","year":"2009","unstructured":"Holmes, C. et al. Systemic inflammation and disease progression in Alzheimer disease. Neurology 73, 768\u2013774 (2009).","journal-title":"Neurology"},{"key":"333_CR131","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1093\/ije\/dyaa241","volume":"50","author":"CHC Yeung","year":"2020","unstructured":"Yeung, C. H. C. & Schooling, C. M. Systemic inflammatory regulators and risk of Alzheimer\u2019s disease: a bidirectional Mendelian-randomization study. Int. J. Epidemiol. 50, 829\u2013840 (2020).","journal-title":"Int. J. Epidemiol."},{"key":"333_CR132","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1089\/jir.2013.0085","volume":"34","author":"M Belkhelfa","year":"2014","unstructured":"Belkhelfa, M. et al. IFN-\u03b3 and TNF-\u03b1 are involved during Alzheimer disease progression and correlate with nitric oxide production: a study in Algerian patients. J. Interferon Cytokine Res 34, 839\u2013847 (2014).","journal-title":"J. Interferon Cytokine Res"},{"key":"333_CR133","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-9-106","volume":"9","author":"D Tweedie","year":"2012","unstructured":"Tweedie, D. et al. Tumor necrosis factor-\u03b1 synthesis inhibitor 3,6\u2019-dithiothalidomide attenuates markers of inflammation, Alzheimer pathology and behavioral deficits in animal models of neuroinflammation and Alzheimer\u2019s disease. J. Neuroinflammation 9, 106 (2012).","journal-title":"J. Neuroinflammation"},{"key":"333_CR134","doi-asserted-by":"publisher","DOI":"10.1186\/s12868-017-0367-y","volume":"18","author":"P-L Chiang","year":"2017","unstructured":"Chiang, P.-L. et al. White matter damage and systemic inflammation in Parkinson\u2019s disease. BMC Neurosci. 18, 48 (2017).","journal-title":"BMC Neurosci."},{"key":"333_CR135","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/bs.pmbts.2020.11.001","volume":"177","author":"G Forloni","year":"2021","unstructured":"Forloni, G., La Vitola, P., Cerovic, M. & Balducci, C. Inflammation and Parkinson\u2019s disease pathogenesis: Mechanisms and therapeutic insight. Prog. Mol. Biol. Transl. Sci. 177, 175\u2013202 (2021).","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"333_CR136","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.neuroscience.2020.02.030","volume":"432","author":"JF Baizabal-Carvallo","year":"2020","unstructured":"Baizabal-Carvallo, J. F. & Alonso-Juarez, M. The Link between Gut Dysbiosis and Neuroinflammation in Parkinson\u2019s Disease. Neuroscience 432, 160\u2013173 (2020).","journal-title":"Neuroscience"},{"key":"333_CR137","doi-asserted-by":"publisher","unstructured":"Wei, Z., Li, X., Li, X., Liu, Q. & Cheng, Y. Oxidative stress in Parkinson\u2019s disease: a systematic review and meta-analysis. Front. in Mol. Neurosci. 11, https:\/\/doi.org\/10.3389\/fnmol.2018.00236 (2018).","DOI":"10.3389\/fnmol.2018.00236"},{"key":"333_CR138","first-page":"544","volume":"47","author":"SC Wall","year":"1995","unstructured":"Wall, S. C., Gu, H. & Rudnick, G. Biogenic amine flux mediated by cloned transporters stably expressed in cultured cell lines: amphetamine specificity for inhibition and efflux. Mol. Pharm. 47, 544\u2013550 (1995).","journal-title":"Mol. Pharm."},{"key":"333_CR139","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1471-2210-6-6","volume":"6","author":"DD Han","year":"2006","unstructured":"Han, D. D. & Gu, H. H. Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs. BMC Pharm. 6, 6 (2006).","journal-title":"BMC Pharm."},{"key":"333_CR140","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/S0376-8716(98)00068-4","volume":"51","author":"SG Amara","year":"1998","unstructured":"Amara, S. G. & Sonders, M. S. Neurotransmitter transporters as molecular targets for addictive drugs. Drug Alcohol Depend. 51, 87\u201396 (1998).","journal-title":"Drug Alcohol Depend."},{"key":"333_CR141","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1006\/frne.1998.0168","volume":"19","author":"BJ Hoffman","year":"1998","unstructured":"Hoffman, B. J., Hansson, S. R., Mezey, E. & Palkovits, M. Localization and dynamic regulation of biogenic amine transporters in the mammalian central nervous system. Front Neuroendocrinol. 19, 187\u2013231 (1998).","journal-title":"Front Neuroendocrinol."},{"key":"333_CR142","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.pneurobio.2005.04.003","volume":"75","author":"D Sulzer","year":"2005","unstructured":"Sulzer, D., Sonders, M. S., Poulsen, N. W. & Galli, A. Mechanisms of neurotransmitter release by amphetamines: a review. Prog. Neurobiol. 75, 406\u2013433 (2005).","journal-title":"Prog. Neurobiol."},{"key":"333_CR143","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1021\/cn300146w","volume":"4","author":"BS Beikmann","year":"2013","unstructured":"Beikmann, B. S., Tomlinson, I. D., Rosenthal, S. J. & Andrews, A. M. Serotonin uptake is largely mediated by platelets versus lymphocytes in peripheral blood cells. ACS Chem. Neurosci. 4, 161\u2013170 (2013).","journal-title":"ACS Chem. Neurosci."},{"key":"333_CR144","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1093\/aje\/kwg068","volume":"157","author":"SK Van Den Eeden","year":"2003","unstructured":"Van Den Eeden, S. K. et al. Incidence of Parkinson\u2019s disease: variation by age, gender, and race\/ethnicity. Am. J. Epidemiol. 157, 1015\u20131022 (2003).","journal-title":"Am. J. Epidemiol."},{"key":"333_CR145","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1212\/01.WNL.0000140706.52798.BE","volume":"63","author":"LM de Lau","year":"2004","unstructured":"de Lau, L. M. et al. Incidence of parkinsonism and Parkinson disease in a general population: the Rotterdam Study. Neurology 63, 1240\u20131244 (2004).","journal-title":"Neurology"},{"key":"333_CR146","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1136\/jnnp.2003.020982","volume":"75","author":"GF Wooten","year":"2004","unstructured":"Wooten, G. F., Currie, L. J., Bovbjerg, V. E., Lee, J. K. & Patrie, J. Are men at greater risk for Parkinson\u2019s disease than women? J. Neurol. Neurosurg. Psychiatry 75, 637\u2013639 (2004).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"333_CR147","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1136\/bmj.321.7252.21","volume":"321","author":"A Schrag","year":"2000","unstructured":"Schrag, A., Ben-Shlomo, Y. & Quinn, N. P. Cross sectional prevalence survey of idiopathic Parkinson\u2019s disease and Parkinsonism in London. Bmj 321, 21\u201322 (2000).","journal-title":"Bmj"},{"key":"333_CR148","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/mds.10087","volume":"17","author":"LE Claver\u00eda","year":"2002","unstructured":"Claver\u00eda, L. E. et al. Prevalence of Parkinson\u2019s disease in Cantalejo, Spain: a door-to-door survey. Mov. Disord. 17, 242\u2013249 (2002).","journal-title":"Mov. Disord."},{"key":"333_CR149","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1002\/mds.10362","volume":"18","author":"J Benito-Le\u00f3n","year":"2003","unstructured":"Benito-Le\u00f3n, J. et al. Prevalence of PD and other types of parkinsonism in three elderly populations of central Spain. Mov. Disord. 18, 267\u2013274 (2003).","journal-title":"Mov. Disord."},{"key":"333_CR150","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1001\/archneur.63.4.584","volume":"63","author":"S Greffard","year":"2006","unstructured":"Greffard, S. et al. Motor score of the Unified Parkinson Disease Rating Scale as a good predictor of Lewy body-associated neuronal loss in the substantia nigra. Arch. Neurol. 63, 584\u2013588 (2006).","journal-title":"Arch. Neurol."},{"key":"333_CR151","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1111\/ene.12476","volume":"22","author":"G Reinoso","year":"2015","unstructured":"Reinoso, G. et al. Clinical evolution of Parkinson\u2019s disease and prognostic factors affecting motor progression: 9-year follow-up study. Eur. J. Neurol. 22, 457\u2013463 (2015).","journal-title":"Eur. J. Neurol."},{"key":"333_CR152","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1002\/mds.10119","volume":"17","author":"ED Louis","year":"2002","unstructured":"Louis, E. D. et al. Diagnosing Parkinson\u2019s disease using videotaped neurological examinations: validity and factors that contribute to incorrect diagnoses. Mov. Disord. 17, 513\u2013517 (2002).","journal-title":"Mov. Disord."},{"key":"333_CR153","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3233\/jpd-2011-11016","volume":"1","author":"S Grill","year":"2011","unstructured":"Grill, S., Weuve, J. & Weisskopf, M. G. Predicting outcomes in Parkinson\u2019s disease: comparison of simple motor performance measures and The Unified Parkinson\u2019s Disease Rating Scale-III. J. Parkinsons Dis. 1, 287\u2013298, https:\/\/doi.org\/10.3233\/jpd-2011-11016 (2011).","journal-title":"J. Parkinsons Dis."},{"key":"333_CR154","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma, R. B. et al. MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov. Disord. 30, 1591\u20131601 (2015).","journal-title":"Mov. Disord."},{"key":"333_CR155","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1002\/mds.28406","volume":"36","author":"WRW Martin","year":"2021","unstructured":"Martin, W. R. W. et al. Is Levodopa Response a Valid Indicator of Parkinson\u2019s Disease? Mov. Disord. 36, 948\u2013954 (2021).","journal-title":"Mov. Disord."},{"key":"333_CR156","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1093\/brain\/awm142","volume":"130","author":"PA Kempster","year":"2007","unstructured":"Kempster, P. A. et al. Patterns of levodopa response in Parkinson\u2019s disease: a clinico-pathological study. Brain 130, 2123\u20132128 (2007).","journal-title":"Brain"},{"key":"333_CR157","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1212\/WNL.0000000000002350","volume":"86","author":"G Rizzo","year":"2016","unstructured":"Rizzo, G. et al. Accuracy of clinical diagnosis of Parkinson disease: a systematic review and meta-analysis. Neurology 86, 566\u2013576 (2016).","journal-title":"Neurology"},{"key":"333_CR158","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1161\/CIRCULATIONAHA.105.594929","volume":"115","author":"KH Zou","year":"2007","unstructured":"Zou, K. H., O\u2019Malley, A. J. & Mauri, L. Receiver-operating characteristic analysis for evaluating diagnostic tests and predictive models. Circulation 115, 654\u2013657 (2007).","journal-title":"Circulation"},{"key":"333_CR159","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1097\/JTO.0b013e3181ec173d","volume":"5","author":"JN Mandrekar","year":"2010","unstructured":"Mandrekar, J. N. Receiver operating characteristic curve in diagnostic test assessment. J. Thorac. Oncol. 5, 1315\u20131316 (2010).","journal-title":"J. Thorac. Oncol."},{"key":"333_CR160","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.neuroscience.2015.05.068","volume":"301","author":"AM Willard","year":"2015","unstructured":"Willard, A. M., Bouchard, R. S. & Gittis, A. H. Differential degradation of motor deficits during gradual dopamine depletion with 6-hydroxydopamine in mice. Neuroscience 301, 254\u2013267 (2015).","journal-title":"Neuroscience"},{"key":"333_CR161","doi-asserted-by":"publisher","unstructured":"Willard, A. M. et al. State transitions in the substantia nigra reticulata predict the onset of motor deficits in models of progressive dopamine depletion in mice. Elife. 8, https:\/\/doi.org\/10.7554\/eLife.42746 (2019).","DOI":"10.7554\/eLife.42746"},{"key":"333_CR162","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1111\/ejn.12459","volume":"39","author":"SR Stott","year":"2014","unstructured":"Stott, S. R. & Barker, R. A. Time course of dopamine neuron loss and glial response in the 6-OHDA striatal mouse model of Parkinson\u2019s disease. Eur. J. Neurosci. 39, 1042\u20131056 (2014).","journal-title":"Eur. J. Neurosci."},{"key":"333_CR163","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/BF03033565","volume":"11","author":"N Simola","year":"2007","unstructured":"Simola, N., Morelli, M. & Carta, A. R. The 6-hydroxydopamine model of Parkinson\u2019s disease. Neurotox. Res 11, 151\u2013167 (2007).","journal-title":"Neurotox. Res"},{"key":"333_CR164","doi-asserted-by":"publisher","unstructured":"da Concei\u00e7\u00e3o, F. S., Ngo-Abdalla, S., Houzel, J. C. & Rehen, S. K. Murine model for Parkinson\u2019s disease: from 6-OH dopamine lesion to behavioral test. J Vis Exp, https:\/\/doi.org\/10.3791\/1376 (2010).","DOI":"10.3791\/1376"},{"key":"333_CR165","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/nprot.2006.342","volume":"2","author":"V Jackson-Lewis","year":"2007","unstructured":"Jackson-Lewis, V. & Przedborski, S. Protocol for the MPTP mouse model of Parkinson\u2019s disease. Nat. Protoc. 2, 141\u2013151 (2007).","journal-title":"Nat. Protoc."},{"key":"333_CR166","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/1055-8330(95)90015-2","volume":"4","author":"V Jackson-Lewis","year":"1995","unstructured":"Jackson-Lewis, V., Jakowec, M., Burke, R. E. & Przedborski, S. Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurodegeneration 4, 257\u2013269 (1995).","journal-title":"Neurodegeneration"},{"key":"333_CR167","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/S0306-4522(96)00545-3","volume":"77","author":"NA Tatton","year":"1997","unstructured":"Tatton, N. A. & Kish, S. J. In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining. Neuroscience 77, 1037\u20131048 (1997).","journal-title":"Neuroscience"},{"key":"333_CR168","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1006\/bbrc.1998.8986","volume":"248","author":"Y Mitsumoto","year":"1998","unstructured":"Mitsumoto, Y., Watanabe, A., Mori, A. & Koga, N. Spontaneous regeneration of nigrostriatal dopaminergic neurons in MPTP-treated C57BL\/6 mice. Biochem Biophys. Res Commun. 248, 660\u2013663 (1998).","journal-title":"Biochem Biophys. Res Commun."},{"key":"333_CR169","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/0006-8993(86)90905-4","volume":"376","author":"GA Ricaurte","year":"1986","unstructured":"Ricaurte, G. A. et al. Fate of nigrostriatal neurons in young mature mice given 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: a neurochemical and morphological reassessment. Brain Res 376, 117\u2013124 (1986).","journal-title":"Brain Res"},{"key":"333_CR170","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/0091-3057(89)90362-6","volume":"34","author":"FB Weihmuller","year":"1989","unstructured":"Weihmuller, F. B., Hadjiconstantinou, M. & Bruno, J. P. Dissociation between biochemical and behavioral recovery in MPTP-treated mice. Pharm. Biochem Behav. 34, 113\u2013117 (1989).","journal-title":"Pharm. Biochem Behav."},{"key":"333_CR171","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3233\/JPD-2011-11023","volume":"1","author":"GE Meredith","year":"2011","unstructured":"Meredith, G. E. & Rademacher, D. J. MPTP mouse models of Parkinson\u2019s disease: an update. J. Parkinsons Dis. 1, 19\u201333 (2011).","journal-title":"J. Parkinsons Dis."},{"key":"333_CR172","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/syn.20089","volume":"55","author":"Z Xu","year":"2005","unstructured":"Xu, Z., Cawthon, D., McCastlain, K. A., Slikker, W. Jr. & Ali, S. F. Selective alterations of gene expression in mice induced by MPTP. Synapse 55, 45\u201351 (2005).","journal-title":"Synapse"},{"key":"333_CR173","doi-asserted-by":"publisher","first-page":"255","DOI":"10.3233\/JPD-130186","volume":"3","author":"D Salat","year":"2013","unstructured":"Salat, D. & Tolosa, E. Levodopa in the treatment of Parkinson\u2019s disease: current status and new developments. J. Parkinsons Dis. 3, 255\u2013269 (2013).","journal-title":"J. Parkinsons Dis."},{"key":"333_CR174","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1586\/ern.09.64","volume":"9","author":"LC Seeberger","year":"2009","unstructured":"Seeberger, L. C. & Hauser, R. A. Levodopa\/carbidopa\/entacapone in Parkinson\u2019s disease. Expert Rev. Neurother. 9, 929\u2013940 (2009).","journal-title":"Expert Rev. Neurother."},{"key":"333_CR175","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1002\/ana.22060","volume":"68","author":"F Stocchi","year":"2010","unstructured":"Stocchi, F. et al. Initiating levodopa\/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann. Neurol. 68, 18\u201327 (2010).","journal-title":"Ann. Neurol."},{"key":"333_CR176","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1212\/01.wnl.0000310812.43352.66","volume":"71","author":"R Katzenschlager","year":"2008","unstructured":"Katzenschlager, R. et al. Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. Neurology 71, 474\u2013480 (2008).","journal-title":"Neurology"},{"key":"333_CR177","doi-asserted-by":"publisher","first-page":"Ii19","DOI":"10.1007\/s00415-002-1204-4","volume":"249","author":"R Katzenschlager","year":"2002","unstructured":"Katzenschlager, R. & Lees, A. J. Treatment of Parkinson\u2019s disease: levodopa as the first choice. J. Neurol. 249, Ii19\u2013Ii24 (2002).","journal-title":"J. Neurol."},{"key":"333_CR178","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1002\/ana.410180505","volume":"18","author":"JG Nutt","year":"1985","unstructured":"Nutt, J. G., Woodward, W. R. & Anderson, J. L. The effect of carbidopa on the pharmacokinetics of intravenously administered levodopa: the mechanism of action in the treatment of parkinsonism. Ann. Neurol. 18, 537\u2013543 (1985).","journal-title":"Ann. Neurol."},{"key":"333_CR179","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.1212\/WNL.58.suppl_1.S19","volume":"58","author":"J Jankovic","year":"2002","unstructured":"Jankovic, J. Levodopa strengths and weaknesses. Neurology 58, S19\u2013S32 (2002).","journal-title":"Neurology"},{"key":"333_CR180","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/j.1600-0404.1993.tb00017.x","volume":"146","author":"A Pletscher","year":"1993","unstructured":"Pletscher, A. & DaPrada, M. Pharmacotherapy of Parkinson\u2019s disease: research from 1960 to 1991. Acta Neurol. Scand. Suppl. 146, 26\u201331 (1993).","journal-title":"Acta Neurol. Scand. Suppl."},{"key":"333_CR181","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1212\/WNL.50.6_Suppl_6.S11","volume":"50","author":"WC Koller","year":"1998","unstructured":"Koller, W. C. & Rueda, M. G. Mechanism of action of dopaminergic agents in Parkinson\u2019s disease. Neurology 50, S11\u2013S14 (1998). discussion S44-18.","journal-title":"Neurology"},{"key":"333_CR182","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1159\/000116170","volume":"27","author":"M Da Prada","year":"1987","unstructured":"Da Prada, M., Kettler, R., Z\u00fcrcher, G., Schaffner, R. & Haefely, W. E. Inhibition of decarboxylase and levels of dopa and 3-O-methyldopa: a comparative study of benserazide versus carbidopa in rodents and of Madopar standard versus Madopar HBS in volunteers. Eur. Neurol. 27, 9\u201320 (1987).","journal-title":"Eur. Neurol."},{"key":"333_CR183","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s007020170056","volume":"108","author":"N Jonkers","year":"2001","unstructured":"Jonkers, N., Sarre, S., Ebinger, G. & Michotte, Y. Benserazide decreases central AADC activity, extracellular dopamine levels and levodopa decarboxylation in striatum of the rat. J. Neural Transm. (Vienna) 108, 559\u2013570 (2001).","journal-title":"J. Neural Transm. (Vienna)"},{"key":"333_CR184","doi-asserted-by":"publisher","first-page":"4499","DOI":"10.4049\/jimmunol.0802740","volume":"182","author":"S Ostrand-Rosenberg","year":"2009","unstructured":"Ostrand-Rosenberg, S. & Sinha, P. Myeloid-derived suppressor cells: linking inflammation and cancer. J. Immunol. 182, 4499\u20134506 (2009).","journal-title":"J. Immunol."},{"key":"333_CR185","doi-asserted-by":"publisher","first-page":"4507","DOI":"10.1158\/0008-5472.CAN-06-4174","volume":"67","author":"P Sinha","year":"2007","unstructured":"Sinha, P., Clements, V. K., Fulton, A. M. & Ostrand-Rosenberg, S. Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res 67, 4507\u20134513 (2007).","journal-title":"Cancer Res"},{"key":"333_CR186","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1126\/science.aag2638","volume":"353","author":"J Kipnis","year":"2016","unstructured":"Kipnis, J. Multifaceted interactions between adaptive immunity and the central nervous system. Science 353, 766\u2013771 (2016).","journal-title":"Science"},{"key":"333_CR187","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1038\/s41593-018-0227-9","volume":"21","author":"A Louveau","year":"2018","unstructured":"Louveau, A. et al. CNS lymphatic drainage and neuroinflammation are regulated by meningeal lymphatic vasculature. Nat. Neurosci. 21, 1380\u20131391 (2018).","journal-title":"Nat. Neurosci."},{"key":"333_CR188","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nature14432","volume":"523","author":"A Louveau","year":"2015","unstructured":"Louveau, A. et al. Structural and functional features of central nervous system lymphatic vessels. Nature 523, 337\u2013341 (2015).","journal-title":"Nature"},{"key":"333_CR189","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1007\/s00702-010-0428-1","volume":"117","author":"L Qian","year":"2010","unstructured":"Qian, L., Flood, P. M. & Hong, J. S. Neuroinflammation is a key player in Parkinson\u2019s disease and a prime target for therapy. J. Neural Transm. (Vienna) 117, 971\u2013979 (2010).","journal-title":"J. Neural Transm. (Vienna)"},{"key":"333_CR190","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1177\/1535370215576313","volume":"240","author":"I Stojkovska","year":"2015","unstructured":"Stojkovska, I., Wagner, B. M. & Morrison, B. E. Parkinson\u2019s disease and enhanced inflammatory response. Exp. Biol. Med (Maywood) 240, 1387\u20131395 (2015).","journal-title":"Exp. Biol. Med (Maywood)"},{"key":"333_CR191","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1038\/jcbfm.2015.128","volume":"35","author":"JH Huck","year":"2015","unstructured":"Huck, J. H. et al. De novo expression of dopamine D2 receptors on microglia after stroke. J. Cereb. Blood Flow. Metab. 35, 1804\u20131811 (2015).","journal-title":"J. Cereb. Blood Flow. Metab."},{"key":"333_CR192","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.mcn.2005.01.003","volume":"29","author":"K F\u00e4rber","year":"2005","unstructured":"F\u00e4rber, K., Pannasch, U. & Kettenmann, H. Dopamine and noradrenaline control distinct functions in rodent microglial cells. Mol. Cell Neurosci. 29, 128\u2013138 (2005).","journal-title":"Mol. Cell Neurosci."},{"key":"333_CR193","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s11481-020-09927-6","volume":"15","author":"EA Nickoloff-Bybel","year":"2020","unstructured":"Nickoloff-Bybel, E. A., Calderon, T. M., Gaskill, P. J. & Berman, J. W. HIV neuropathogenesis in the presence of a disrupted dopamine system. J. Neuroimmune Pharm. 15, 729\u2013742 (2020).","journal-title":"J. Neuroimmune Pharm."},{"key":"333_CR194","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.brainres.2018.04.030","volume":"1702","author":"R Nolan","year":"2019","unstructured":"Nolan, R. & Gaskill, P. J. The role of catecholamines in HIV neuropathogenesis. Brain Res 1702, 54\u201373 (2019).","journal-title":"Brain Res"},{"key":"333_CR195","doi-asserted-by":"publisher","first-page":"739","DOI":"10.2174\/1567205013666160222112444","volume":"13","author":"D Goldeck","year":"2016","unstructured":"Goldeck, D., Witkowski, J. M., F\u00fclop, T. & Pawelec, G. Peripheral immune signatures in Alzheimer disease. Curr. Alzheimer Res 13, 739\u2013749 (2016).","journal-title":"Curr. Alzheimer Res"},{"key":"333_CR196","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1002\/ana.20369","volume":"57","author":"R Kortekaas","year":"2005","unstructured":"Kortekaas, R. et al. Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann. Neurol. 57, 176\u2013179 (2005).","journal-title":"Ann. Neurol."},{"key":"333_CR197","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1172\/JCI58644","volume":"122","author":"RM Ransohoff","year":"2012","unstructured":"Ransohoff, R. M. & Brown, M. A. Innate immunity in the central nervous system. J. Clin. Invest 122, 1164\u20131171 (2012).","journal-title":"J. Clin. Invest"},{"key":"333_CR198","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/nri1130","volume":"3","author":"RM Ransohoff","year":"2003","unstructured":"Ransohoff, R. M., Kivis\u00e4kk, P. & Kidd, G. Three or more routes for leukocyte migration into the central nervous system. Nat. Rev. Immunol. 3, 569\u2013581 (2003).","journal-title":"Nat. Rev. Immunol."},{"key":"333_CR199","doi-asserted-by":"publisher","unstructured":"Mogensen, F. L., Delle, C. & Nedergaard, M. The glymphatic system (En)during inflammation. Int J Mol Sci 22, https:\/\/doi.org\/10.3390\/ijms22147491 (2021).","DOI":"10.3390\/ijms22147491"},{"key":"333_CR200","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s00401-018-1812-4","volume":"135","author":"NJ Abbott","year":"2018","unstructured":"Abbott, N. J., Pizzo, M. E., Preston, J. E., Janigro, D. & Thorne, R. G. The role of brain barriers in fluid movement in the CNS: is there a \u2018glymphatic\u2019 system? Acta Neuropathol. 135, 387\u2013407 (2018).","journal-title":"Acta Neuropathol."},{"key":"333_CR201","doi-asserted-by":"publisher","first-page":"147ra111","DOI":"10.1126\/scitranslmed.3003748","volume":"4","author":"JJ Iliff","year":"2012","unstructured":"Iliff, J. J. et al. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid \u03b2. Sci. Transl. Med 4, 147ra111 (2012).","journal-title":"Sci. Transl. Med"},{"key":"333_CR202","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.imbio.2006.05.025","volume":"211","author":"F Tacke","year":"2006","unstructured":"Tacke, F. & Randolph, G. J. Migratory fate and differentiation of blood monocyte subsets. Immunobiology 211, 609\u2013618 (2006).","journal-title":"Immunobiology"},{"key":"333_CR203","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1093\/intimm\/dxy063","volume":"30","author":"S Kawamura","year":"2018","unstructured":"Kawamura, S. & Ohteki, T. Monopoiesis in humans and mice. Int Immunol. 30, 503\u2013509 (2018).","journal-title":"Int Immunol."}],"container-title":["npj Parkinson's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41531-022-00333-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-022-00333-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-022-00333-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T19:30:33Z","timestamp":1700681433000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41531-022-00333-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,7]]},"references-count":203,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["333"],"URL":"https:\/\/doi.org\/10.1038\/s41531-022-00333-8","relation":{},"ISSN":["2373-8057"],"issn-type":[{"value":"2373-8057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,7]]},"assertion":[{"value":"15 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing non-financial interests, but the following financial interests: G.S. holds equity in EnCor Biotechnology, Inc, a company commercializing certain antibodies used in this study, and may benefit by receiving royalties or equity growth. H.K. and A.G. are included in an intellectual property filing related to some flow cytometry methods and procedures used in this study. H.K. is an inventor on the pending US patent application serial number 17\/630,321, which covers the subject of this work. All other authors declare no conflicts.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"72"}}